Search

Your search keyword '"Ashare, Alix"' showing total 254 results

Search Constraints

Start Over You searched for: Author "Ashare, Alix" Remove constraint Author: "Ashare, Alix"
254 results on '"Ashare, Alix"'

Search Results

1. Mrs4 loss of function in fungi during adaptation to the cystic fibrosis lung

3. Model Systems to Study the Chronic, Polymicrobial Infections in Cystic Fibrosis: Current Approaches and Exploring Future Directions

4. Healthy versus inflamed lung environments differentially affect mesenchymal stromal cells

5. Model Systems to Study the Chronic, Polymicrobial Infections in Cystic Fibrosis: Current Approaches and Exploring Future Directions.

6. Aspergillus fumigatus In-Host HOG Pathway Mutation for Cystic Fibrosis Lung Microenvironment Persistence.

7. Balancing Positive and Negative Selection: In Vivo Evolution of Candida lusitaniae MRR1

8. Balancing positive and negative selection: in vivo evolution of Candida lusitaniae MRR1

9. Evolution of drug resistance in an antifungal-naive chronic Candida lusitaniae infection

10. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

13. Early Urinary Markers of Kidney Injury in Adult People with Cystic Fibrosis Correlate with Neutrophil Activation and Lung Infection

14. Characterization of SARS-CoV-2 Convalescent Patients’ Serological Repertoire Reveals High Prevalence of Iso–RBD Antibodies

15. Lung function and microbiota diversity in cystic fibrosis

25. Model Systems to Study the Chronic, Polymicrobial Infections in Cystic Fibrosis: Current Approaches and Exploring Future Directions

26. A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment

29. Aspergillus fumigatusIn-Host HOG pathway mutation for Cystic Fibrosis Lung Microenvironment Persistence

30. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

32. Healthy versus inflamed lung environments differentially affect mesenchymal stromal cells

33. Healthy versus inflamed lung environments differentially affect mesenchymal stromal cells

35. Anti-inflammatory response is associated with mortality and severity of infection in sepsis

39. Differential effects of the cystic fibrosis lung inflammatory environment on mesenchymal stromal cells

46. List of Contributors

47. Additional file 1 of Lung function and microbiota diversity in cystic fibrosis

48. Balancing positive and negative selection:in vivoevolution ofCandida lusitaniae MRR1

49. Additional file 5 of Lung function and microbiota diversity in cystic fibrosis

50. Additional file 2 of Lung function and microbiota diversity in cystic fibrosis

Catalog

Books, media, physical & digital resources